Astellas, Pfizer Sue Sun to Block Copies of Xtandi Drug (1)

Astellas Pharma Inc., Pfizer Inc.’s Medivation, and the University of California allege that copies of Xtandi proposed by Sun Pharmaceutical Industries Ltd. infringe a patent for the prostate cancer drug, whose US sales added nearly $1.2 billion to Pfizer’s 2021 revenue.

Sun wants to sell generic versions of Xtandi’s 40- and 80-milligram tablets, according to a complaint filed Dec. 16 in the US District Court for the District of New Jersey. Xtandi also is available in a 40-mg capsule, but that formulation isn’t at play in the suit against Sun.

Xtandi’s active ingredient, enzalutamide, was developed by UC, which ...